Suplementos para el resfriado y la gripe

Foro general ciencia, medicina, nutrición, salud pública, política

Moderador: Fisio

Re: Suplementos para el resfriado y la gripe

Notapor Fisio » Mié, 12 Nov 2014, 18:34

Equinacea en Cochrane 2014, se ve algún indicio de efecto, es poco, pero podría ser por falta de poder estadístico

exploratory meta analysis across products suggests that Echinacea products may be associated with a small reduction in cold incidence and that individual trials seem to be underpowered. The overall evidence for clinically relevant treatment effects is weak. We updated the search in July 2014, but could not identify more recent randomized clinical trials on Echinacea for preventing or treating the common cold.

Echinacea for preventing and treating the common cold.
Karsch-Völk M1, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K, Linde K.
Author information

Echinacea plant preparations (family Asteraceae) are widely used in Europe and North America for common colds. Most consumers and physicians are not aware that products available under the term Echinacea differ appreciably in their composition, mainly due to the use of variable plant material, extraction methods and the addition of other components.

To assess whether there is evidence that Echinacea preparations are effective and safe compared to placebo in the prevention and treatment of the common cold.

We searched CENTRAL 2013, Issue 5, MEDLINE (1946 to May week 5, 2013), EMBASE (1991 to June 2013), CINAHL (1981 to June 2013), AMED (1985 to February 2012), LILACS (1981 to June 2013), Web of Science (1955 to June 2013), CAMBASE (no time limits), the Centre for Complementary Medicine Research (1988 to September 2007), WHO ICTRP and (last searched 5 June 2013), screened references and asked experts in the field about published and unpublished studies.

Randomized controlled trials (RCTs) comparing mono-preparations of Echinacea with placebo.

At least two review authors independently assessed eligibility and trial quality and extracted data. The primary efficacy outcome was the number of individuals with at least one cold in prevention trials and the duration of colds in treatment trials. For all included trials the primary safety and acceptability outcome was the number of participants dropping out due to adverse events. We assessed trial quality using the Cochrane 'Risk of bias' tool.

Twenty-four double-blind trials with 4631 participants including a total of 33 comparisons of Echinacea preparations and placebo met the inclusion criteria. A variety of different Echinacea preparations based on different species and parts of plant were used. Evidence from seven trials was available for preparations based on the aerial parts of Echinacea purpurea. Ten trials were considered to have a low risk of bias, six to have an unclear risk of bias and eight to have a high risk of bias. Ten trials with 13 comparisons investigated prevention and 15 trials with 20 comparisons investigated treatment of colds (one trial addressed both prevention and treatment).Due to the strong clinical heterogeneity of the studies we refrained from pooling for the main analysis. None of the 12 prevention comparisons reporting the number of patients with at least one cold episode found a statistically significant difference. However a post hoc pooling of their results, suggests a relative risk reduction of 10% to 20%. Of the seven treatment trials reporting data on the duration of colds, only one showed a significant effect of Echinacea over placebo. The number of patients dropping out or reporting adverse effects did not differ significantly between treatment and control groups in prevention and treatment trials. However, in prevention trials there was a trend towards a larger number of patients dropping out due to adverse events in the treatment groups.

Echinacea products have not here been shown to provide benefits for treating colds, although, it is possible there is a weak benefit from some Echinacea products: the results of individual prophylaxis trials consistently show positive (if non-significant) trends, although potential effects are of questionable clinical relevance.
Avatar de Usuario
Administrador del Sitio
Mensajes: 4987
Registrado: Dom, 01 Sep 2013, 14:18

Re: Suplementos para el resfriado y la gripe

Notapor nick74 » Dom, 04 Ene 2015, 19:24

Mensajes: 177
Registrado: Jue, 03 Abr 2014, 12:06

Re: Suplementos para el resfriado y la gripe

Notapor Fisio » Vie, 23 Oct 2015, 00:22

Actualizado con probioticos

La ultima revisión de 2015 con metodología Cochrane encuentra efectividad en general en infecciones de tracto alto y bajo en niños ... 5715000686

Cochrane también ... ommon-cold

También en un estudio con probióticos y vitamina C ... 4174a.html

De Vrese 2006 reducción de los días de sintomatología de los procesos catarrales, siendo 9 días la media de aquellos que tomaron un placebo, y de 7 el grupo que tomó probióticos. Las fracciones protéicas del yogurt, especialmente la lactoferrina, inmunoglobulinas y alfa lactoalbúminas, elevan los niveles de glutatión y tienen propiedades antivíricas, bactericidas y antimicrobianas.
Avatar de Usuario
Administrador del Sitio
Mensajes: 4987
Registrado: Dom, 01 Sep 2013, 14:18


Volver a Muscleblog

¿Quién está conectado?

Usuarios navegando por este Foro: No hay usuarios registrados visitando el Foro y 3 invitados